Biogen Idec (NASDAQ: BIIB) has initiated the Phase III clinical program of BG-12, an oral fumarate in development for relapsing-remitting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE